Know Cancer

or
forgot password

Analysis of ABCG2 Genotype in Gleevec Treated Cancer Patients to Assess the Association of a Single Nucleotide Polymorphism (C421A) in ABCG2 and Response to Treatment


N/A
18 Years
N/A
Not Enrolling
Both
Cancer, Breast Cancer

Thank you

Trial Information

Analysis of ABCG2 Genotype in Gleevec Treated Cancer Patients to Assess the Association of a Single Nucleotide Polymorphism (C421A) in ABCG2 and Response to Treatment


ABCG2, also known as breast cancer resistance protein (BCRP), is an ATP-binding cassette
(ABC) transporter that has been shown to confer resistance to several drugs, including
mitoxantrone and topotecan. Gleevec (imatinib mesylate) has recently been identified as a
substrate for ABCG2. The expression of ABCG2 in the human jejunum has been shown to be
higher than expression MDR1, which encodes for P-glycoprotein. Therefore, it is plausible
that the oral bioavailability of Gleevec could be dependent on the extent of transport. A
single nucleotide polymorphism (C421A) has been identified in ABCG2 and has been shown in
vitro to result in functional inactivation of this transporter protein. In this study, the
relationship between the genotypes of ABCG2 and the pharmacokinetics or side effects will be
retrospectively explored in patients with cancer who had been previously enrolled on
clinical trials of Gleevec.

Inclusion Criteria


- INCLUSION CRITERIA:

In this retrospective study, all cancer patients enrolled on IRB approved clinical trials
of Gleevec from both the National Cancer and outside institutions will be eligible,
provided that they have consented in the original consent form.

EXCLUSION CRITERIA:

Not applicable.

Type of Study:

Observational

Study Design:

N/A

Authority:

United States: Federal Government

Study ID:

999905090

NCT ID:

NCT00342056

Start Date:

January 2005

Completion Date:

October 2008

Related Keywords:

  • Cancer
  • Breast Cancer
  • Pharmacogenetics
  • Transporter Proteins
  • Drug Exposure
  • Imatinib
  • Retrospective
  • Cancer
  • Breast Neoplasms

Name

Location

Washington Hospital CenterWashington, District of Columbia  20010